A Phase 1 Study to Evaluate the Efficacy and Safety Of AB-101, an Allogeneic Cord Blood Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Chian Kwoh
Sponsor
Artiva Biotherapeutics, Inc
Unit
Arthritis Center-Research